As the global obesity epidemic continues to escalate, the development of effective obesity management solutions has become a front and centre topic in the life sciences sector. With over 650 million adults worldwide classified as obese, the demand for innovative therapeutic approaches is as high as it’s ever been. This demand has been evident with the huge commercial success of Ozempic and Wegovy, which has driven a wave of investment into developing new therapeutics in the obesity space.
More and more, obesity is being understood as not just a matter of excess weight, but a complex metabolic disorder that might require medical intervention. Traditional interventions like diet and exercise, while crucial, don’t always offer the comprehensive solution needed for significant, sustainable weight loss. This gap underscores the necessity for pharmacological interventions that can work in conjunction with lifestyle changes to combat obesity effectively.
In this race to develop therapies that at the forefront of innovation, we are now seeing companies like Poolbeg Pharma plc.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
